You will also be interested
[EN VIDÉO] HIV: the first case of cure? A Brazilian diagnosed 8 years ago could possibly be cured of HIV in the long term!
Moderna is with Pfizer one of the two pharmaceutical companies to have successfully developed a vaccine at mRNA. This is of course the vaccine against SARS-CoV-2. This vaccine has demonstrated excellent efficacy, at least against the original strain of the virus that was in circulation at the time of its launch. With a large number of injections in record time, the security profile of the product is under control. Building on this success, the company launched a program of several HIV vaccines based on the same technology.
A vaccine targeting a surface protein
The trial that has just started will include 100 healthy adult people. The objective is to establish the safety profile and the quality of the immune response of three different vaccine formulations. Each participant will receive three doses of vaccine over a period of six months.
Like the SARS-CoV-2 vaccine targets the Spike surface protein to prevent the virus from entering the cell, the HIV vaccine targets a virus surface protein. This is much more complex than the Spike protein.
This test is different from the one launched by the same company in January, although both are HIV vaccines based on mRNA technology. Moderna’s other ongoing trial aims to stimulate B cells.
Interested in what you just read?